Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables - Other: 2017-2025

Historic Receivables - Other for Autolus Therapeutics (AUTL) over the last 2 years, with Sep 2025 value amounting to $936,000.

  • Autolus Therapeutics' Receivables - Other rose 56.52% to $936,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $936,000, marking a year-over-year increase of 56.52%. This contributed to the annual value of $1.4 million for FY2024, which is 175.39% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Receivables - Other of $936,000 as of Q3 2025, which was up 40.75% from $665,000 recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Receivables - Other peaked at $2.4 million during Q3 2023, and registered a low of $354.38 during Q1 2021.
  • Moreover, its 3-year median value for Receivables - Other was $736,000 (2024), whereas its average is $956,556.
  • Per our database at Business Quant, Autolus Therapeutics' Receivables - Other soared by 273.70% in 2022 and then plummeted by 74.63% in 2024.
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Receivables - Other stood at $384,000 in 2021, then surged by 273.70% to $1.4 million in 2022, then plummeted by 64.04% to $516,000 in 2023, then surged by 175.39% to $1.4 million in 2024, then spiked by 56.52% to $936,000 in 2025.
  • Its Receivables - Other was $936,000 in Q3 2025, compared to $665,000 in Q2 2025 and $423,000 in Q1 2025.